More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.61B
EPS
-14.27
P/E ratio
--
Price to sales
0.27
Dividend yield
--
Beta
3.031505
Previous close
$93.79
Today's open
$95.20
Day's range
$91.18 - $96.48
52 week range
$7.48 - $133.04
show more
CEO
Steven J. Sell
Employees
856
Headquarters
Westerville, OH
Exchange
New York Stock Exchange
Shares outstanding
16791210
Issue type
Common Stock
Healthcare
Healthcare Providers & Services
agilon health to Participate in Upcoming Conferences
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that its management team will participate in a fireside chat at the following conferences: Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. 2026 Jefferies Healthcare Services and Technology Conference on Monday, September 14, 2026. A live webcast will be available on the company's investor relati.
Business Wire • Aug 20, 2026

Has Agilon Health (AGL) Outpaced Other Medical Stocks This Year?
Here is how Agilon Health (AGL) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Zacks Investment Research • Aug 12, 2026

agilon health: The Q2 Inflection Is Real
agilon Health delivered a strong Q2 2026 with revenue of $1.49B, a $250M YoY medical margin swing, and raised FY26 guidance across all key metrics. AGL's operational turnaround is supported by improved cost trends, enhanced data pipelines, and clinical pathway execution, notably reducing inpatient first-diagnosis rates from 25% to under 5%. Balance sheet strength is evident with over $220M net cash, while disciplined membership management supports ongoing profitability.
Seeking Alpha • Aug 7, 2026

Agilon Health Q2 Earnings Call Highlights
Agilon Health NYSE: AGL reported second-quarter results that exceeded its guidance for medical margin and adjusted EBITDA, citing stronger risk-adjustment revenue, favorable medical-cost development and progress in its clinical and quality initiatives. The company also raised its full-year 2026 outlook.
MarketBeat • Aug 6, 2026

agilon health, inc. (AGL) Q2 2026 Earnings Call Transcript
agilon health, inc. (AGL) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 6, 2026

agilon health Reports Second Quarter 2026 Results
WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the second quarter ended June 30, 2026. In addition, the company increased full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA. “Our second quarter results exceeded our expectations, demonstrating meaningful progress across agilon's strategic initiatives and reinforcing our confidence i.
Business Wire • Aug 5, 2026

Agilon (AGL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Agilon (AGL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Aug 6, 2026

Agilon Health (AGL) Tops Q2 Earnings and Revenue Estimates
Agilon Health (AGL) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $6.25 per share a year ago.
Zacks Investment Research • Aug 6, 2026

Did agilon health, inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
PRNewsWire • Jul 29, 2026

Kaskela Law Firm Announces Investigation of Agilon Health, Inc. (AGL) and Encourages Long-Term AGL Shareholders with Investment Losses to Contact the Firm
PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Agilon Health, Inc. (NYSE: AGL) (“Agilon”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/agilon-health/ Recently a securities fraud complaint was filed against Agilon on behalf of certain investors who purchased shares of the company's stock between April 15, 2021 and February 27, 2024. According to the complaint, during that.
Business Wire • Jul 23, 2026

¹ Disclosures

Open an M1 investment account to buy and sell agilon health inc. commission-free¹. Build wealth for the long term using automated trading and transfers.